MRK vs PTGX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PTGX exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9 and a fortress-like balance sheet (Current Ratio 12.71, Debt/Equity 0.02). However, the company is in a speculative pre-commercial phase, evidenced by a staggering Price/Sales ratio of 146.96 and negative profit margins. While analysts maintain a 'strong_buy' based on the late-stage pipeline (Icotyde and Rusfertide), significant insider selling by the CEO and CFO creates a divergence between institutional optimism and internal sentiment.
Compare Another Pair
Related Comparisons
MRK vs PTGX: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Protagonist Therapeutics, Inc. (PTGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.